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Abstract
The Na/dicarboxylate cotransporter of the renal proximal tubule, NaDC-1, reabsorbs Krebs cycle intermediates, such as
succinate and citrate, from the tubular filtrate. Although long-term regulation of this transporter by chronic metabolic
acidosis and K deficiency is well documented, there is no information on acute regulation of NaDC-1. In the present study,
the transport of succinate in Xenopus oocytes expressing NaDC-1 was inhibited up to 95% by two activators of protein kinase
C, phorbol 12-myristate, 13-acetate (PMA) and sn-1,2-dioctanoylglycerol (DOG). Activation of protein kinase A had no
effect on NaDC-1 activity. The inhibition of NaDC-1 transport by PMA was dose-dependent, and could be prevented by
incubation of the oocytes with staurosporine. Mutations of the two consensus protein kinase C phosphorylation sites in
NaDC-1 did not affect inhibition by PMA. The inhibitory effects of PMA were partially prevented by cytochalasin D, which
disrupts microfilaments and endocytosis. PMA treatment was also associated with a decrease of approximately 30% in the
amount of NaDC-1 protein found on the plasma membrane. We conclude that the inhibition of NaDC-1 transport activity
by PMA occurs by a combination of endocytosis and inhibition of transport activity. ß 1999 Elsevier Science B.V. All
rights reserved.
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1. Introduction
The Na/dicarboxylate cotransporter of the renal
proximal tubule, NaDC-1, reabsorbs Krebs cycle in-
termediates, such as succinate and citrate, from the
tubular ¢ltrate [1]. This transporter couples three so-
dium ions to the movement of one substrate mole-
cule, carried as a divalent anion. One of the functions
of NaDC-1 is in regulating the concentration of uri-
nary citrate, an endogenous inhibitor of calcium
stone formation [2,3]. The transport of citrate by
NaDC-1 is stimulated by acidic pH [4,5]. One mech-
anism for this transport activation is an increase in
the concentration of the preferred substrate, cit-
rate23, as the pH is decreased. However, there is
also evidence that chronic metabolic acidosis stimu-
lates citrate uptake by inducing transporter activity
[6], which is the result of an increase in NaDC-1
mRNA and protein [7]. Other chronic conditions,
such as K de¢ciency and starvation, also stimulate
citrate transport [7^9]. The stimulation of citrate
transport in chronic K depletion has also been
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shown to result from increased NaDC-1 mRNA and
protein abundance [10].
In contrast to the number of studies on chronic
e¡ects on NaDC-1 activity, however, there is no in-
formation on acute changes in transporter activity.
Short-term regulation of membrane transporter ac-
tivity can be mediated by direct modulation of the
transporter protein, such as phosphorylation, or by
changes in the abundance of the transporter at the
plasma membrane. For example, the glutamate
transporters, GLT-1 and GLAST-1, and the dopa-
mine transporter, DAT, are directly phosphorylated
in response to protein kinase C activation [11^13].
There are also examples of regulation of transporter
activity by altered targeting of the proteins to or
from the plasma membrane. The activities of the
GABA transporter, GAT-1 [14,15], the Na/glucose
cotransporter, SGLT1 [16], and the Na/H ex-
changer, NHE3 [17] are regulated by insertion or
removal processes. In the serotonin transporters,
SERTs, phosphorylation and endocytosis of trans-
porter protein are both observed when protein kinase
C is activated, which implies that the phosphoryla-
tion state of the SERTs determines their tra⁄cking
in the cell [18].
In the present study, the short-term e¡ects of pro-
tein kinases on NaDC-1 activity were investigated.
NaDC-1 is acutely inhibited by activators of protein
kinase C and relatively insensitive to activation of
protein kinase A. Although NaDC-1 contains two
consensus sequences for phosphorylation by protein
kinase C, these sites do not mediate the inhibition of
transport by protein kinase C. Disruption of micro-
tubules with cytochalasin D prevents some of the
e¡ects of phorbol 12-myristate, 13-acetate (PMA).
Furthermore, the activation of protein kinase C is
accompanied by a 30% decrease of NaDC-1 protein
at the cell surface, indicating that part of the inhib-
ition is due to endocytosis of the transporter. The
remaining reduction of NaDC-1 activity most likely
occurs by direct inhibition of the transporter activity.
2. Materials and methods
2.1. Xenopus oocytes
Stage V and VI oocytes from Xenopus laevis were
dissected and collagenase treated as described previ-
ously [19]. Oocytes were cultured at 18‡C in Barth’s
medium supplemented with 5% heat-inactivated
horse serum, 2.5 mM sodium pyruvate and 50 mg/l
gentamicin [19]. Culture dishes and medium were
changed daily.
2.2. In vitro cRNA transcription
The wild-type and mutant NaDC-1 cDNAs in
pSPORT plasmid were used as templates for cRNA
synthesis [19]. Plasmids were linearized with NotI
and in vitro cRNA transcription was done using
the T7 mMessage mMachine Kit (Ambion). The
cRNAs were resuspended in water to a ¢nal concen-
tration of 0.5^1 Wg/Wl.
2.3. Transport experiments
Transport of [14C]succinate (DuPont-NEN) was
measured 5^7 days after oocyte injections, also as
described [19]. Sodium and choline bu¡ers (in mM)
were as follows: 100 NaCl or cholineCl, 2 KCl,
1 MgCl2, 1 CaCl2, 10 HEPES-Tris, pH 7.5. The oo-
cytes were rinsed brie£y with choline bu¡er to re-
move sodium and serum. Transport was initiated
by replacement of the choline rinse with 0.4 ml of
the appropriate transport bu¡er as described in the
¢gure legends. Transport was stopped by the addi-
tion of 4 ml ice-cold choline bu¡er followed by re-
moval of extracellular radioactivity with three addi-
tional washes in cold choline bu¡er. Individual
oocytes were transferred to scintillation vials and dis-
solved in 0.5 ml 10% SDS. Scintillation cocktail was
added and radioactivity was counted. Counts in con-
trol uninjected oocytes were subtracted from the
counts in cRNA-injected oocytes. Data are presented
as means þ S.E.M. Statistical analysis was done using
the SigmaStat Program (Jandel Scienti¢c).
2.4. PMA experiments
Xenopus oocytes were preincubated at room tem-
perature in Barth’s solution containing PMA (usually
50 nM) dissolved in dimethylsulfoxide (DMSO).
Control oocytes were incubated in Barth’s solution
containing DMSO alone (the amount of DMSO was
1 Wl/ml of solution). The PMA or DMSO-containing
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solution was removed with four washes of choline
bu¡er at room temperature, after which the trans-
port bu¡er was added. To determine the e¡ects of
di¡erent drugs, the oocytes were treated with the test
compound before the incubation with PMA. Stauro-
sporine or okadaic acid stock solutions were pre-
pared in DMSO. Oocytes were preincubated in
Barth’s solution containing DMSO alone, or con-
taining okadaic acid (1 WM), or staurosporine (10
and 20 WM) for 1 h at room temperature. Colchicine
and cytochalasin D stock solutions were prepared in
ethanol. In those experiments, oocytes were preincu-
bated in Barth’s solution containing either ethanol
alone, colchicine (20 WM) for 5 h or cytochalasin D
(20 WM) for 1 h at 18‡C. After the ¢rst incubation
with the test agents, the solutions were removed with
three washes of room temperature choline bu¡er.
The oocytes were then incubated for 30 min at
room temperature in Barth’s solution containing
DMSO or PMA dissolved in DMSO. The solutions
were again removed with three washes of choline
bu¡er and the transport bu¡er containing
[14C]succinate was added for measurement of succi-
nate uptakes.
2.5. Site-directed mutagenesis
The two consensus sites for protein kinase C phos-
phorylation in NaDC-1 [19], Thr-186 and Ser-366,
were altered by site-directed mutagenesis. The muta-
genesis was done using the oligonucleotide-directed
method [20] with reagents from the Muta-Gene plas-
mid kit from Bio-Rad, according to manufacturer’s
directions. The sequences of the oligonucleotides
used in the mutagenesis procedure were: (Mutant
P1) 5P-CACCTTGCTGTTTTCCTTCTGGGG-3P
and (Mutant P2) 5P-GACTCTCCCGTTGGCGTC-
GGAGAA-3P. The identity of the mutants, T186N
and S366N, was veri¢ed by sequencing. The mutants
are designated using the single letter amino acid code
followed by the number indicating the position of the
residue in wild-type NaDC-1. The second letter fol-
lowing the sequence number indicates the amino acid
replacement at that position.
2.6. Cell surface biotinylation of oocytes
The cell surface expression of NaDC-1 was tested
using a membrane impermeant reagent, Sulfo-NHS-
LC-Biotin (Pierce), as described [21]. For each bio-
tinylation experiment, groups of ¢ve oocytes were
rinsed three times with 4 ml ice-cold phosphate-bu¡-
ered saline, pH 8 (PBS) [21]. The oocytes were then
incubated 10 min at room temperature in 0.5 ml PBS
containing 0.5 mg/ml Sulfo-NHS-LC-Biotin. The
biotinylation reagent was removed with four washes
of 4-ml ice-cold PBS. The oocytes were then dis-
solved in lysis bu¡er (150 mM NaCl, 20 mM Tris-
HCl, pH 7.6, 1% Triton X-100) for 30 min on ice.
The solubilized oocytes were centrifuged 15 min at
14 000Ug and the supernatants transferred to new
tubes. The biotinylated proteins were incubated
with 50 Wl ImmunoPure Immobilized Streptavidin
beads (Pierce) for 1 h at 4‡C. The biotin^streptavi-
din^agarose bead complexes were washed four times
by suspension in lysis bu¡er followed by centrifuga-
tion. The ¢nal pellets were resuspended in the appro-
priate sample bu¡er and boiled 5 min before being
loaded onto a polyacrylamide gel for SDS-PAGE
[22].
2.7. Western blots of cell surface proteins
The transporters precipitated by the biotinylation^
streptavidin precipitation procedures were identi¢ed
by Western blotting as described previously [22].
Brie£y, oocyte proteins were separated by SDS-
PAGE and blotted onto nitrocellulose [22]. The ni-
trocellulose membranes were blocked for a minimum
of 1 h in PBS-TM (phosphate-bu¡ered saline con-
taining 0.05% Tween 20 and 0.5% Carnation instant
dried milk). The Western blots were probed with an
antibody directed against a fusion protein of NaDC-
1, which was raised in rabbits [23]. The primary anti-
body was diluted 1:10 000 in PBS-TM, and applied
for 1 h, after which the secondary antibody, horse-
radish peroxidase-linked anti-rabbit Ig (Amersham),
was diluted 1:10 000 in PBS-TM and applied for 1 h.
All incubations and washes were done at room tem-
perature. Antibody binding was visualized by en-
hanced chemiluminescence using the Supersignal
CL-HRP substrate system (Pierce). Molecular
weights were estimated by comparison with pre-
stained protein standards (Bio-Rad). The Western
blots were scanned with a Microtek Scanmaker E3
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scanner, and peak mass and intensity were calculated
using SigmaGel software (Jandel Scienti¢c).
3. Results
The regulation of NaDC-1 activity by protein kin-
ases was tested by measuring the e¡ect of protein
kinase activators on succinate transport in Xenopus
oocytes expressing NaDC-1. As shown in Fig. 1, pre-
incubation of oocytes with the protein kinase C acti-
vators, phorbol 12-myristate, 13-acetate (PMA) or
sn-1,2-dioctanoylglycerol (DOG) [24,25], resulted in
an inhibition of succinate transport by approxi-
mately 80%. In the same oocytes, stimulation of pro-
tein kinase A with 8-bromo-cAMP caused only a
minor stimulation, approximately 10%, of succinate
transport by NaDC-1 (Fig. 1). Treatment of oocytes
with vehicle alone (0.1% DMSO) had no e¡ect on
succinate transport (not shown). The inhibitory e¡ect
of PMA on succinate transport by NaDC-1 was
dose-dependent, with approximately 50% inhibition
seen at 12 nM PMA (Fig. 2). The maximal inhibition
was approximately 95% at 50 nM PMA (Fig. 2).
Staurosporine is a membrane-permeable, broad-
speci¢city inhibitor of protein kinases, including pro-
tein kinase C [26]. As shown in Fig. 3, preincubation
of oocytes with 10 WM staurosporine partially pre-
vented the inhibition seen with PMA, whereas 20 WM
staurosporine completely prevented the e¡ects of
PMA. Therefore, a protein kinase, most likely pro-
tein kinase C, is involved in mediating the inhibitory
e¡ect of PMA. Oocytes expressing NaDC-1 were
also treated with okadaic acid before being incubated
with PMA. Okadaic acid, which inhibits protein
phosphatases [27], should potentiate the e¡ects of
PMA. However, okadaic acid had no e¡ect on the
response of the oocytes to PMA (Fig. 3). Okadaic
acid was also ine¡ective in altering the response of
NaDC-1 to a lower concentration of PMA (25 nM)
(not shown). Both okadaic acid and staurosporine
had slight inhibitory e¡ects (5 and 14%, respectively)
on succinate transport by NaDC-1 (not shown), sug-
gesting that the endogenous activity of protein kin-
ases in the oocytes may a¡ect transport activity of
NaDC-1.
The sequence of NaDC-1 contains two consensus
Fig. 2. Concentration dependence of inhibition by PMA. Oo-
cytes expressing NaDC-1 were preincubated with up to 50 nM
PMA, as described in Section 2. Succinate transport was meas-
ured for 30 min. The uptake rates are expressed as percentage
of uptakes in control oocytes, which were incubated with
DMSO only (1673 þ 35 pmol/oocyte/h, n = 5).
Fig. 1. E¡ect of protein kinase activators on succinate transport
by NaDC-1. Xenopus oocytes expressing NaDC-1 were preincu-
bated 30 min with Barth’s solution containing DMSO (con-
trols), 50 nM PMA, 10 WM DOG, or 2 mM 8-Br-cAMP. The
preincubation bu¡ers were washed away and transport of 100
WM succinate was measured over 30 min. Uptakes are ex-
pressed as percentage of control uptake rates (318 þ 23 pmol/oo-
cyte/h, n = 5).
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sites for phosphorylation by protein kinase C, at
Thr-186 and Ser-366 [19,28]. According to the cur-
rent secondary structure model of NaDC-1, Thr-186
is located in a cytoplasmic loop, between transmem-
brane domains 4 and 5, and Ser-366 is located in an
extracellular loop, between transmembrane domains
7 and 8. To test whether the e¡ects of PMA on
succinate transport by NaDC-1 are mediated
through either of these potential phosphorylation
sites, each of these residues was mutated to an aspar-
agine. Both mutant transporters exhibited succinate
transport activity that was almost as high as the
wild-type NaDC-1 (Fig. 4), indicating that Thr-186
and Ser-366 are not required for transport activity or
protein targeting. There was no di¡erence in PMA
sensitivity between the wild-type NaDC-1 and
T186N and S366N mutant transporters (Fig. 4).
Therefore, the inhibitory e¡ects of PMA on NaDC-
1 are independent of phosphorylation of the protein
kinase C consensus sites.
One possible mechanism for the inhibition of
NaDC-1 activity by PMA is by endocytosis of cell
surface transporters. Two agents that a¡ect protein
tra⁄cking through the cell were tested for their abil-
ity to prevent the e¡ects of PMA on succinate trans-
port (Fig. 5). Colchicine, which acts by disrupting
microtubule polymerization, had no e¡ect on inhib-
ition of succinate transport by PMA. However, cy-
tochalasin D, which disrupts micro¢laments, parti-
ally prevented the inhibitory e¡ect of PMA on
succinate transport (Fig. 5). In four separate experi-
ments, PMA inhibited transport to 9 þ 2% of control
in the absence of cytochalasin D, but after incuba-
tions with both cytochalasin D and PMA the trans-
port was only inhibited to 42 þ 8% of control.
The cell surface expression of NaDC-1 after treat-
ment with PMA was monitored with a membrane
impermeant derivative of biotin, sulfo-NHS-LC-bio-
tin, followed by Western blotting of the cell-surface
proteins with a speci¢c anti-NaDC-1 antibody. There
was a dose-dependent reduction in the amount of
NaDC-1 protein expressed at the plasma membrane
Fig. 4. Sensitivity to PMA inhibition by wild-type NaDC-1 and
phosphorylation site mutants, T186N and S366N. Oocytes were
preincubated 30 min in Barth’s solution containing DMSO
(controls) or 37.5 nM PMA. Transport of 100 WM succinate
was then measured during the next 30 min. When expressed as
percentage of control for each group, the activity remaining
after PMA treatment was 3.2% (NaDC-1), 4.5% (T186N) and
5.4% (S366N). Data shown are means þ S.E., n = 5 oocytes.
Fig. 3. The inhibitory e¡ect of PMA can be prevented by stau-
rosporine. Xenopus oocytes expressing NaDC-1 were preincu-
bated with okadaic acid (OKA, 1 WM) or staurosporine
(STAURO, 10 and 20 WM), or DMSO alone (controls) as de-
scribed in Section 2. The oocytes were then incubated with or
without 50 nM PMA. Finally, the transport of 100 WM succi-
nate was measured for 30 min. The results show the succinate
activity remaining after PMA treatment expressed as a percent
of transport activity in the absence of PMA (mean þ S.E.M.,
n = 3^5 batches of oocytes). The asterisk () indicates a signi¢-
cant di¡erence, P6 0.05, in the staurosporine-treated groups
compared with vehicle-treated controls.
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after incubation with PMA (Fig. 6). Western blots of
NaDC-1 expressed in oocytes typically have two pro-
tein bands, in this case at 76 and 55 kDa, that rep-
resent di¡erently glycosylated forms of the transport-
er [22]. The total NaDC-1 protein was reduced 6%
(10 nM PMA), 19% (25 nM PMA) and 32% (50 nM
PMA). Both glycosylated forms of NaDC-1 were
reduced by a similar amount. For example, after
treatment with 50 nM PMA, the 76 kDa protein
was reduced by 27% and the 55 kDa protein was
reduced by 31%. Therefore, the reduction of
NaDC-1 activity after PMA treatment is partly ac-
counted for by the removal of transporter protein
from the plasma membrane.
4. Discussion
The Na/dicarboxylate cotransporter, NaDC-1,
expressed in Xenopus oocytes is subject to regulation
by activators of protein kinase C. A marked inhib-
ition of succinate transport was seen when oocytes
expressing NaDC-1 were treated with the phorbol
ester, PMA, or with the diacylglycerol analog,
DOG. The e¡ects of PMA could be prevented by
staurosporine, suggesting that the activation of a
protein kinase, probably protein kinase C, is in-
volved in the inhibition of NaDC-1 activity. The
mechanism of inhibition of NaDC-1 appears to be
a combination of a decrease in the amount of protein
at the plasma membrane and an inhibitory e¡ect on
the activity of the transporter itself.
Approximately one-third of the inhibition of
NaDC-1 by phorbol esters can be accounted for by
endocytosis of the transporter from the plasma mem-
brane. Cell surface biotinylation of oocytes showed a
maximal reduction in NaDC-1 protein by about 30%
at the highest concentration of PMA. The e¡ects of
PMA on NaDC-1 activity were partially prevented
by cytochalasin D, which acts by disrupting actin
micro¢laments. Actin micro¢laments have been
shown to play important roles in the endocytic path-
ways from apical membranes of polarized cells [29].
There was no e¡ect of colchicine on the reduction of
NaDC-1 activity by PMA. Colchicine has been
shown to a¡ect microtubule polymerization and exo-
cytic pathways in cells, including exocytosis of the
Na/phosphate cotransporter, NaPi-2 [30]. A de-
crease in the amount of protein at the plasma mem-
brane could be due to decreased exocytosis or in-
creased endocytosis or a combination of both.
Therefore, the e¡ect of cytochalasin D and lack of
e¡ect of colchicine suggests that the decrease in
Fig. 6. Cell surface expression of NaDC-1 in control (DMSO-
treated) and PMA-treated oocytes. Oocytes were treated with
PMA (at 10, 25 or 50 nM) in DMSO or DMSO alone (0 PMA
condition) as described in Section 2, after which the cell surface
proteins were biotinylated with sulfo-NHS-LC-biotin. The pro-
teins were then precipitated with streptavidin^agarose and run
on Western blots. Blots were probed with 1:10 000 dilution of
primary antibody followed by 1:10 000 dilution of secondary
antibody.
Fig. 5. E¡ects of colchicine or cytochalasin D on PMA-induced
inhibition of NaDC-1 activity. Oocytes expressing NaDC-1
were preincubated with Barth’s medium containing 20 WM col-
chicine or 20 WM cytochalasin D dissolved in ethanol or etha-
nol alone, as described in Section 2. The oocytes were then
treated with 50 nM PMA dissolved in DMSO or DMSO alone.
After the second preincubation, the oocytes were again washed
and transport of 100 WM succinate was measured for a 15-min
time period. The asterisk () indicates a signi¢cant di¡erence,
P6 0.05, between PMA treatment in the presence and absence
of cytochalasin D.
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NaDC-1 protein in the plasma membrane is likely to
be mediated by increased endocytosis.
Changes in protein tra⁄cking in response to acti-
vation of protein kinase C appear to be a common
mechanism in changes in the activity of a large num-
ber of transporters. However, the proportion of
transport activity a¡ected by protein tra⁄cking com-
pared with direct e¡ects on protein activity varies
with speci¢c proteins. In many transporters, all or
most of the changes in transport activity can be ac-
counted for by changes in the amount of protein in
the plasma membrane. For example, in response to
PKC stimulation the rabbit Na/glucose cotrans-
porter SGLT1 is inhibited whereas the human
hSGLT1 is stimulated, both of which are correlated
with changes in transporter protein in the plasma
membrane [16]. The GABA transporter, GAT-1, is
stimulated by activation of PKC through increased
insertion into the plasma membrane [15]. In the tau-
rine transporter, removal of the transporter from the
plasma membrane in response to activation of PKC
accounts for approximately 80% of the transport in-
hibition [31]. However, other transporters show a
combination of direct and indirect e¡ects on protein
activity in response to protein kinase C activation.
The sodium^proton exchanger, NHE-3, exhibits a
decrease in Vmax after PKC activation [17]. Approx-
imately 50% of the reduction is accounted for by
endocytosis from the plasma membrane to a cyto-
plasmic compartment, which suggests that the other
50% of the decrease in Vmax is likely to be due to a
decrease in turnover number. Serotonin transporters
are phosphorylated and rapidly internalized, in par-
allel with the loss of activity, in response to activa-
tion of protein kinase C [18,32]. However, it is not
known whether the phosphorylation state is the sig-
nal for changes in transporter distribution or if the
phosphorylated proteins show changes in activity.
Most of the inhibition of transport activity of
NaDC-1 appears to be the result of a direct e¡ect
on the transporter’s activity. The transporter protein
is present at the plasma membrane, but the activity is
reduced. One potential mechanism for modulating
the activity of NaDC-1 is by phosphorylation. There
are examples of transporters whose activity is directly
modulated by changes in phosphorylation state. The
glutamate transporter, GLT-1, is phosphorylated in
response to activation of protein kinase C and trans-
port activity is proportional to the amount of phos-
phorylated protein [11]. The high-a⁄nity glutamate
transporter, GLAST-1, is also inhibited by direct
phosphorylation of the transporter in response to
phorbol ester treatment [12]. In NaDC-1, because
some of the reduction of transport activity is medi-
ated by a reduction in protein, it is possible that the
inhibition of transport activity and internalization
could be related. For example, phosphorylation of
the transporter could lead to inhibition of function
and also serve as an internalization signal, although
this remains to be tested.
The inhibition of succinate transport by PMA in
NaDC-1 is not mediated through either of the pro-
tein kinase C consensus phosphorylation sequences.
Mutagenesis of Thr-186 and Ser-366 to remove the
potential phosphorylation sites did not alter the in-
hibition of transport after PMA incubation. One
possible explanation is that PKC phosphorylates
proteins at sites other than the consensus sites, as
seen in the K1 isoform of the Na,K-ATPase [33].
Alternately, the activated protein kinase C could act
on other kinases that then phosphorylate NaDC-1 or
it could act on an inhibitory protein that is activated
by phosphorylation. In most cases, however, the ef-
fects of PKC on transporter activity are independent
of phosphorylation consensus sites, with the excep-
tion of the GABA transporter, GAT-1, which is
phosphorylated at a protein kinase C consensus site
[11].
The renal Na/dicarboxylate cotransporter exhib-
its adaptive changes in activity in response to chronic
treatments such as metabolic acidosis, potassium de-
¢ciency (which causes an extracellular alkalosis and
an intracellular acidosis), and starvation [7^9]. The
transport of citrate is increased in renal brush-border
membrane vesicles in response to these treatments,
mediated by an increased Vmax with no change in
Km. Preliminary experiments show that the increased
activity of NaDC-1 is due to an increase in both
mRNA and protein abundance, suggesting regula-
tion of gene transcription and translation [7,10]. In
this study, acute changes in protein kinase C activity
caused changes in NaDC-1 activity that were inde-
pendent of gene regulation or protein translation.
The results suggest that protein kinase C mediated
pathways are likely to be involved in rapid modula-
tion of NaDC-1 activity.
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In conclusion, the activity of the rabbit renal
brush-border Na/dicarboxylate cotransporter,
NaDC-1, expressed in Xenopus oocytes is very sensi-
tive to inhibition by activators of protein kinase C,
but not by activation of protein kinase A. The mech-
anism of this inhibition is independent of consensus
sequences for protein kinase C phosphorylation.
However, the inhibition occurs by a combination of
microtubule-dependent endocytosis of NaDC-1 from
the plasma membrane and a direct inhibition of
transport activity. The results of this study suggest
that NaDC-1 is likely to be regulated by acute
changes in protein kinase C activity in vivo.
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